One in three suffers from a brain disease or cancer and currently there are no “cures” as drugs do not reach the brain at viable doses. The clinical translation success rate of new drugs for brain diseases remains the lowest of all therapeutic areas and current animal models are unreliable to inform translation. Our proprietary patented GFiberS platform technology enables the on-target non-invasive nose-to-brain delivery of peptide therapies for brain diseases and tumours. GFiberS are manufactured under continuous and industrial amenable processes and our team is pioneering proprietary human organ-on-chip nose-to-brain models for speeding up the translation of brain therapies.
Company Details
- Employees
- 1
- Founded
- -
- Address
- 161 Cathedral Street, Glasgow,scotland,united Kingdom
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Keywords
- San Francisco.
- HQ
- Glasgow, Scotland
Gfibers Questions
Gfibers's LinkedIn profile is https://uk.linkedin.com/company/gfibers
Gfibers has
1 employees.
View email and phone details for 1
employees at Gfibers.
Gfibers's industry is
Pharmaceutical Manufacturing
Gfibers's top competitors are
Google Fiber,
Microsoft,
Waymo,
Amazon,
Youtube,
Google,
Segra,
Verily,
Deutsche Bank,
Wells Fargo.
Gfibers's categories are Pharmaceutical Manufacturing
Gfibers's founding year is 2023
